HLA-DRB1 Alleles Are Associated with the Susceptibility to Sporadic Parkinson’s Disease in Chinese Han Population

Congcong Sun1, Lei Wei1,2, Feifei Luo1,3, Yi Li4, Jiaobiao Li5, Feiqi Zhu6, Ping Kang7, Rensi Xu8, LuLu Xiao9, Zhuolin Liu1, Pingyi Xu1*

1 Department of Neurology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China, 2 Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China, 3 Department of Neurology, He’nan University of Traditional Chinese Medicine, Zhengzhou, People’s Republic of China, 4 Department of Neurology, Department of Neurology, Red-Cross Hospital in Guangzhou, Guangzhou, People’s Republic of China, 5 Department of Neurology, He’nan University of Traditional Chinese Medicine, Zhengzhou, People’s Republic of China, 6 Department of Neurology, Yuebei People’s Hospital of Shantou University Medical College, Guangdong, People’s Republic of China, 7 Department of Neurology, The First People’s Hospital of Shaoqian, Guangdong, People’s Republic of China, 8 Department of Neurology, The First Affiliated Hospital of NanChang University, NanChang, People’s Republic of China, 9 Department of Tissue Typing Center, Nanfang Hospital of Southern Medical University, Guangzhou, People’s Republic of China

Abstract

Immune disorders may play an important role in the pathogenesis of Parkinson’s disease (PD). Recently, polymorphisms in the HLA-DR region have been found to be associated with sporadic PD in European ancestry populations. However, polymorphisms in the HLA complex are highly variable with ethnic and geographic origin. To explore the relationships between polymorphisms of the HLA-DR region and sporadic PD in Chinese Han population, we genotyped 567 sporadic PD patients and 746 healthy controls in two independent series for the HLA-DRB1 locus with Polymerase chain reaction-sequence based typing (PCR-SBT). The χ² test was used to evaluate the distribution of allele frequencies between the patients and healthy controls. The impact of HLA-DRB1 alleles on PD risk was estimated by unconditional logistic regression. We found a significant higher frequency of HLA-DRB1*0301 in sporadic PD patients than in healthy controls and a positive association, which was independent of onset age, between HLA-DRB1*0301 and PD risk. Conversely, a lower frequency of HLA-DRB1*0406 was found in sporadic PD patients than in healthy controls, with a negative association between HLA-DRB1*0406 and PD risk. Furthermore, a meta-analysis involving 195205 individuals was conducted to summarize the frequencies of these two alleles in populations from various ethnic regions, we found a higher frequency of HLA-DRB1*0301, but a lower frequency of HLA-DRB1*0406 in European ancestry populations than that in Asians, this was consistent with the higher prevalence of sporadic PD in European ancestry populations. Based on these results, we speculate that HLA-DRB1 alleles are associated with the susceptibility to sporadic PD in Chinese Han population, among them HLA-DRB1*0301 is a risk allele while the effect of HLA-DRB1*0406 deserves debate.

Introduction

Parkinson’s disease (PD), the second most common human neurodegenerative disease, is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra (SN) and other brainstem nuclei [1]. To date, the exact etiology of sporadic PD still remains unknown. Immune dysfunctions have been confirmed to be one of the causes of this disease [2–4]. In the brain of PD patients, large numbers of microglia expressing human leucocyte antigen (HLA)-DR have been detected in the SN, particularly in areas of maximal neurodegeneration [5]. The HLA-DR antigen, encoded by HLA-DRA and HLA-DRB alleles, belongs to HLA class II molecules and acts as an antigen-presenting molecule or regulatory molecule involved in the specific immune response and innate immune response [6]. The highly polymorphic HLA complex plays an important role in genetic susceptibility to human diseases, and different alleles of HLA loci are responsible to variable immune responses among individuals [7].

Associations between genotype of HLA loci and degenerative diseases in the central nerve system (CNS) have been found in many populations. For example, the association between HLA-A*01, A*2402, HLA-DRB1*03 or DRB1*1501 and high risk for Alzheimer disease has been reported [8–11]. Possible associations of HLA-A*2 and A*28, HLA-B*17 and B*18, and HLA-DQB1*06 with PD have also been reported [12–15]. However, in those studies, the enrolled subjects were relatively small by low-
resolution genotyping analysis, and therefore, the conclusions could be ambiguous. Recently, Saiki et al. found that HLA-DRB1*03 was more common among British PD patients than healthy controls with low-resolution typing [16]. In addition, large-scale genome-wide association studies indicated that genetic susceptibility loci for late-onset sporadic PD might have existed in the HLA-DR region, such as rs3129882 in HLA-DRA and chr6:32588205 in HLA-DRB5 [17–19]. These studies suggest that the HLA-DR region is susceptible to the development of PD in European ancestry populations.

However, the HLA complex is highly polymorphic with different ethnic and geographic origins, PD genome-wide association studies (GWAS) study in Japanese shown no evidence of HLA association [20], while the relationship between HLA-DR polymorphism and PD in Chinese Han population has not yet been extensively investigated. Because HLA-DRB1 is the most polymorphic locus in the HLA-DR region [21], we systematically analyzed the polymorphism of HLA-DRB1 alleles among sporadic PD patients and healthy controls from a Han population living in the Guangdong province of the People’s Republic of China (PRC) to avoid an alpha inflation when chaining statistical tests, the potential association of HLA-DRB1 alleles with PD in this population was evaluated, and gender and the onset age were taken into account.

Materials and Methods

Patients
A total of 567 sporadic PD patients and 746 unrelated healthy controls of Han population root from Guangdong province of the PRC were enrolled for this study (Basic information shown in Table 1). Each subject signed an informed consent before participating. The Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University approved the protocol for this study. All PD patients were diagnosed according to the modified UK Brain Bank criteria [22] at the Parkinson Clinic Center in the First Affiliated Hospital of Sun Yat-sen University from 2007 to 2012. The healthy controls were randomly selected from blood donor volunteers in the health examination center of The First Affiliated Hospital of Sun Yat-sen University. The average age of the PD patients and healthy controls was 62.20 ± 19.10 years (range: 16–88) and 38.32 ± 14.30 years (range: 18–85) respectively.

DNA Extraction and HLA Typing
Whole blood samples were collected from PD patients and healthy controls. Genomic DNA was extracted from 4 ml of whole blood using the QIA-amp DNA Mini Kit (QIAGEN, German) according to the manufacturer’s protocols. Extracted genomic DNA samples were stored at −80°C until genotyping was performed. The primer pairs recommended by the International Histocompatibility Working Group (HWG) were used to subtype the alleles of HLA-DRB1. HLA-DRB1 allele groups were typed by polymerase chain reaction-sequence-based typing (PCR-SBT) described previously [23]. Briefly, 22 group-specific primer pairs were used to amplify exon 2 of HLA-DRB1 using a thermal cycler (model 9700, Applied Biosystems, Foster City, CA, USA). PCR products were purified by incubating them with exonuclease at 37°C for 30 min and then with shrimp alkaline phosphatase (SAP) at 80°C for 15 min. We sequenced each purified PCR product using the ABI BigDye Terminatorv3.1 Cycle Sequencing Kit (Applied Biosystems, USA) and the ABI Prism 3100 Genetic Analyzer (Applied Biosystems). The sequence data were analyzed using the Match Tools and Navigator software (Match Tools Allele Identification package, Applied Biosystems, USA).

Table 1. Basic information of patients with sporadic Parkinson’s disease (PD) and healthy controls.

| Sample size | Series1 | Series2 | Combination |
|-------------|---------|---------|-------------|
|             | PD      | Control | PD          | Control |
| Total       | 374     | 503     | 193         | 243     |
| Onset age≤50 (Male/Female) | 74(31/43) | 113(76/37) | 33(11/22) | 58(20/38) |
| Onset age>50 (Male/Female) | 300(177/123) | 390(240/150) | 160(66/94) | 185(75/110) |

Table 1: Basic information of patients with sporadic Parkinson’s disease (PD) and healthy controls.

| Sample size | Series1 | Series2 | Combination |
|-------------|---------|---------|-------------|
|             | PD      | Control | PD          | Control |
| Total       | 374     | 503     | 193         | 243     |
| Onset age≤50 (Male/Female) | 74(31/43) | 113(76/37) | 33(11/22) | 58(20/38) |
| Onset age>50 (Male/Female) | 300(177/123) | 390(240/150) | 160(66/94) | 185(75/110) |

Statistical Analyses

Alleles were tested for deviation from Hardy-Weinberg equilibrium (HWE) using the SHEsis software platform [24]. Phenotype Frequency was defined as the total number of carriers in the population (Carriers/n), Allele Frequency was defined as the total number of copies of the allele in the population sample (Alleles/2n). The χ2 test was used to evaluate the distribution of allele frequencies between the patients and healthy controls, The Fisher exact test was used when expected frequencies were less than five. In addition, Bonferroni adjusted p values (pc) were used to avoid an alpha inflation when chaining statistical tests, the number of chaining statistical tests was defined as the number of the detected alleles. The association between PD and alleles was represented by odds ratio (OR), which was estimated by unconditional logistic models adjusted for the age of onset and gender. Statistical power of every allele can be calculated by the formula: 

\[
\text{Power} = 1 - \beta \quad ,
\]

where \(\beta\) is the type I error rate, \(\alpha\) is the significance level. Calculations were carried out using SPSS-13.0 software (SPSS Inc., Chicago, IL). A \(p_c<0.05\), statistic Power>0.75 was regarded as statistically significant.

Results

The Distribution of HLA-DRB1 Alleles between PD Patients and Healthy Controls

HLA-DRB1 genotype frequencies in both PD patients and healthy controls in two series were remained constant according to
Table 2. Frequencies of HLA-DRB1 phenotypes and alleles in patients with Parkinson’s disease (PD) and healthy controls.

| HLA-DRB1 Alleles | Series 1 | Series 2 | Combination |
|------------------|----------|----------|-------------|
|                  | PD N = 374 | Control N = 503 | P/Pc | PD N = 193 | Control N = 243 | P/Pc |
| 0101             | –        | –        | –        | 4(0.0053) | 120(0.0119) | ns |
| 0102             | –        | 2(0.0020) | –        | –        | –        | ns |
| 0301             | 63(0.0869) | 48(0.0477) | 0.001/0.041 | 27(0.0699) | 18(0.0391) | 0.025/ns 9.728E-5/4.572E-3 |
| 0304             | –        | 1(0.0010) | –        | –        | –        | ns |
| 0401             | 3(0.0040) | 10(0.0099) | ns        | 2(0.0052) | 7(0.0144) | ns |
| 0402             | –        | 1(0.0010) | –        | –        | –        | ns |
| 0403             | 23(0.0307) | 16(0.0159) | 0.035/ns  | 15(0.0389) | 9(0.0185) | ns 0.005/ns |
| 0404             | 14(0.0187) | 11(0.0109) | ns        | 6(0.0155) | 3(0.0062) | ns |
| 0405             | 38(0.0508) | 47(0.0467) | ns        | 18(0.0466) | 26(0.0535) | ns |
| 0406             | 1(0.0013) | 30(0.0308) | 8.036E-7/3.295E-5 | 3(0.0078) | 12(0.0267) | 0.097/ns 3.229E-6/1.518E-4 |
| 0407             | –        | 1(0.0010) | –        | –        | –        | ns |
| 0410             | –        | 1(0.0010) | –        | 1(0.0021) | ns        |
| 0701             | 36(0.0495) | 53(0.0567) | ns        | 19(0.0570) | 38(0.0823) | ns |
| 0702             | –        | 2(0.0020) | –        | –        | –        | ns |
| 0801             | –        | 2(0.002) | –        | –        | –        | ns |
| 0802             | 3(0.0040) | 5(0.0050) | ns        | –        | 1(0.0021) | ns |
| 0803             | 53(0.0749) | 70(0.0716) | ns        | 31(0.0881) | 36(0.0802) | ns |
| 0809             | 1(0.0013) | 5(0.0050) | ns        | –        | –        | ns |
| 0901             | 115(0.1618) | 159(0.167) | ns        | 57(0.1580) | 84(0.1831) | ns |
| 1001             | 7(0.0094) | 16(0.0159) | ns        | 3(0.0078) | 7(0.0144) | ns |
| 1101             | 34(0.0455) | 50(0.0507) | ns        | 19(0.0492) | 21(0.0432) | ns |
| 1104             | –        | 2(0.0020) | ns        | 1(0.0026) | –        | ns |
| 1106             | 2(0.0027) | –        | ns        | –        | –        | ns |
| 1201             | 25(0.0334) | 46(0.0497) | ns        | 10(0.0259) | 18(0.0370) | ns |
| 1202             | 80(0.1123) | 81(0.0875) | 0.045/ns  | 33(0.0907) | 41(0.0885) | ns ns |
| 1218             | 3(0.0040) | –        | ns        | –        | –        | ns |
| 1220             | –        | –        | ns        | –        | 1(0.0021) | ns |
| 1301             | 2(0.0027) | 8(0.0080) | ns        | 4(0.0104) | 2(0.0041) | ns |
| 1302             | 17(0.0227) | 34(0.0348) | ns        | 10(0.0259) | 16(0.0329) | ns |
| 1305             | –        | 1(0.0010) | ns        | –        | –        | ns |
| 1312             | 14(0.0187) | 8(0.0080) | 0.044/ns  | 7(0.0181) | 5(0.0103) | 0.027/ns |
| 1403             | 3(0.0040) | 4(0.0040) | ns        | 1(0.0026) | 3(0.0062) | ns |
| 1404             | 4(0.0053) | 8(0.0080) | ns        | 3(0.0078) | 3(0.0062) | ns |
| 1405             | 21(0.0281) | 19(0.0189) | ns        | 12(0.0311) | 10(0.0206) | ns |
| 1406             | –        | –        | ns        | –        | 1(0.0021) | ns |
| 1407             | –        | 2(0.0020) | ns        | –        | 2(0.0041) | ns |
| 1410             | –        | –        | ns        | –        | 1(0.0021) | ns |
| 1418             | –        | 4(0.0040) | ns        | –        | –        | ns |
| 1422             | –        | 1(0.0010) | ns        | –        | –        | ns |
| 1454             | 28(0.0428) | 21(0.0209) | 0.035/ns  | 15(0.0389) | 13(0.0288) | ns 0.021/ns |
| 1501             | 75(0.1016) | 111(0.1183) | ns        | 42(0.1192) | 50(0.1111) | ns |
| 1502             | 27(0.0361) | 33(0.0328) | ns        | 12(0.0311) | 13(0.0267) | ns |
| 1504             | –        | 1(0.0010) | ns        | 1(0.0026) | –        | ns |
| 1545             | –        | –        | ns        | –        | 1(0.0021) | ns |
| 1601             | –        | –        | ns        | –        | 1(0.0021) | ns |
| 1602             | 30(0.0414) | 41(0.0427) | ns        | 19(0.0492) | 19(0.0391) | ns |

Phenotype Frequency (Allele Frequency) was present in every cell. “-” : the allele was not been detected. Phenotype Frequency: Percentage of individuals who have the allele (Individuals/N) in percentage format. Allele Frequency: Total number of copies of the allele in the population sample (Alleles/2N) in decimal format, Pc = correction of P value (Bonferroni adjustment), Pc < 0.05 is considered as significant, ns = not significant. Patients had significant higher frequencies of HLA-DRB1*0301 and lower frequency of HLA-DRB1*0406 than healthy controls did.

doi:10.1371/journal.pone.0048594.t002
HWE. A total of 46 HLA-DRB1 alleles were detected in all studied individuals, among them 41 alleles were detected in series 1, 34 alleles were detected in series 2.

We found that PD patients presented higher allele frequencies of HLA-DRB1*0301 (0.0069 vs. 0.0477, \( p = 0.001 \) in series 1, 0.0659 vs. 0.0391, \( p = 0.025 \) in series 2, 0.0011 vs. 0.0449, \( p = 9.728E-5 \) in combined series 1 and series 2), DRB1*0403 (0.0307 vs. 0.0139, \( p = 0.053 \) in series 1), DRB1*1202 (0.1123 vs. 0.0875, \( p = 0.045 \) in series 1), DRB1*1312 (0.0137 vs. 0.0080, \( p = 0.044 \) in series 1), and DRB1*1454 (0.0428 vs. 0.0209, \( p = 0.035 \) in series 1) than the healthy controls. Conversely, the HLA-DRB1*0406 was found with lower allele frequency in PD patients compared to healthy controls (0.0013 vs. 0.0308, \( p = 8.036E-7 \) in series 1, 0.0078 vs. 0.0267, \( p = 0.097 \) in series 2, 0.0055 vs. 0.0295, \( p = 3.229E-6 \) in combined series 1 and series 2).

However, after Bonferroni adjustment only the differences of allele frequency between PD subgroups (onset age \( \leq 50 \)) and healthy control subgroups (onset age \( \leq 50 \)) was statistically significant (\( \text{Pc} = 0.020, \text{Power} > 0.75 \), respectively) (Fig.1). Using stratification analyses and unconditional logistic regression analysis adjusted for gender, we found that the positive association between HLA-DRB1*0301 and PD risk was independent of onset age (onset age \( \leq 50 \); OR = 3.350, P = 4.039E-4, onset age >50; OR = 1.726, P = 0.007).

The Allele Frequencies of HLA-DRB1*0301 and HLA-DRB1*0406 in Populations from Various Ethnic Regions

To get the allele distribution of HLA-DRB1*0301 and HLA-DRB1*0406 in worldwide populations, we conducted a meta-analysis to summarize the allele frequencies of HLA-DRB1*0301 and HLA-DRB1*0406 in populations from various ethnic regions. A systemic literature review was made to identify 32 studies involving 195205 individuals met criteria for the meta analysis. The inclusion criteria was (i) randomised trial, no selection bias. (ii) subjects were all collected from healthy adult volunteers, and sample size \( \geq 500 \). (iii) protocols for HLA-DRB1 genotyping: High-resolution genotyping analysis. (iv) confirm to Hardy-Weinberg equilibrium. (v) The allele frequencies were calculated by direct gene counting method. (vi) The allele frequencies of HLA-DRB1*0301 and HLA-DRB1*0406 were calculated by direct gene counting method.

The Relationship between HLA-DRB1*0301 and PD Risk

To further analyze the relationship between HLA-DRB1*0301 and PD risk, we compared the allele frequencies of HLA-DRB1*0301 between subgroups classified by the gender and the onset age of all subjects through 20 independent \( \chi^2 \) tests and statistic power calculation described previously. We found that the allele frequencies of HLA-DRB1*0301 were higher in both PD subgroups (onset age \( \leq 50 \) and onset age >50) than in their healthy control subgroups (0.0676 vs. 0.0263, \( p = 0.001 \), 0.0342 vs. 0.0213, \( p = 0.006 \), respectively), these differences were only occurred in male subgroups (0.0892 vs. 0.0266, \( p = 0.001 \), 0.0412 vs. 0.0230, \( p = 0.014 \), respectively). More interestingly, we found that the allele frequency of HLA-DRB1*0301 was higher in patients with an onset age \( \leq 50 \) than in patients with an onset age >50 (0.0678 vs. 0.0342, \( p = 0.001 \) for all patients, 0.0892 vs. 0.0412, \( p = 0.003 \) for male patients and 0.0538 vs. 0.0265, \( p = 0.046 \) for female patients). After Bonferroni adjustment, the differences of allele frequency between PD subgroups (onset age \( \leq 50 \)) and healthy control subgroups (onset age \( \leq 50 \)) was statistically significant (\( \text{Pc} = 0.020 \) and \( \text{Pc} = 0.020 \), \text{statistic Power} > 0.75, respectively) (Fig.1). Using stratification analyses and unconditional logistic regression analysis adjusted for gender, we found that the positive association between HLA-DRB1*0301 and PD risk was independent of onset age (onset age \( \leq 50 \); OR = 3.350, P = 4.039E-4, onset age >50; OR = 1.726, P = 0.007).

Figure 1. Comparison of the allele frequencies of HLA-DRB1*0301 among various groups. All subjects were classified by gender and age of onset of Parkinson’s disease (PD). \( \triangle \text{Pc}<0.05 \) the allele frequency of HLA-DRB1*0301 in PD patients(total) vs. the one in healthy control(total), *\( \text{Pc}<0.05 \) the allele frequency of HLA-DRB1*0301 in PD patients (onset age \( \leq 50 \)) vs. the one in healthy control subgroup (onset age \( \leq 50 \)), # \( \text{Pc}<0.05 \) the allele frequency of HLA-DRB1*0301 in PD patients (onset age \( \leq 50 \)) vs. the one in PD patients (onset age >50).

\( \text{doi:10.1371/journal.pone.0048594.g001} \)
detected all together. The Excluding criteria was (i) the basic information (eg. race, region) of subjects was unclear. (ii) there was a limitation in subject collections (eg. gender, age, smoker) (iii) the calculation method for allele frequency was unspecified. Calculations were carried out using Stata-11.0 software (StataCorp, College Station, TX, USA). Using a meta-analysis, we found that (i) the distribution of HLA-DRB1*0301 and HLA-DRB1*0406 was inequality in populations from various ethnic regions: European ancestry populations presented a higher allele frequency of HLA-DRB1*0301 than African and Latin American ancestry populations and Asians (0.114 Vs. 0.071, 0.069, 0.041). In intra-Asian, Taiwanese presented a higher allele frequency of HLA-DRB1*0301 than populations in USA, mainland China, and Korea (0.091 Vs 0.054, 0.047, 0.022). However, HLA-DRB1*0301 was a rare allele in Japanese.

doi:10.1371/journal.pone.0048594.g002

Figure 2. Forest plots summarizing the Allele frequency of HLA-DRB1*0301 in Asian and European ancestry populations from various regions. The allele frequency was indicated as ES (95%CI). The distribution of HLA-DRB1*0301 was inequality in the worldwide populations, European ancestry populations presented a higher allele frequency of HLA-DRB1*0301 than African and Latin American ancestry populations and Asians (0.114 Vs. 0.071, 0.069, 0.041). In intra-Asian, Taiwanese presented a higher allele frequency of HLA-DRB1*0301 than populations in USA, mainland China, and Korea (0.091 Vs. 0.054, 0.047, 0.022). However, HLA-DRB1*0301 was a rare allele in Japanese.

doi:10.1371/journal.pone.0048594.g003

Figure 3. Forest plots summarizing the Allele frequency of HLA-DRB1*0406 in Asian and European ancestry populations from various regions. The allele frequency was indicated as ES (95%CI). The distribution of HLA-DRB1*0406 was inequality in the worldwide populations, it was common in Asians but rare in African, Latin American and European ancestry populations (0.031 Vs. 0.001, 0.002, 0.001). In intra-Asian, Korean presented a higher allele frequency of HLA-DRB1*0406 than populations from Japan, China Taiwan, mainland China, and USA (0.060 Vs. 0.032, 0.029, 0.025, 0.021).

doi:10.1371/journal.pone.0048594.g003
Table 3. The allele frequencies of HLA-DRB1*0301 and HLA-DRB1*0406 in populations from various ethnic regions.

| Author          | Ethnic origin | Geographic Region                        | Size | Allele Frequency |
|-----------------|---------------|------------------------------------------|------|------------------|
| A. L.Hei [25]   | Asian         | China(Beijing,Suzhou,Shenzhen)           | 718  | 0.0369           |
| Y. Liu [26]     | Asian         | North China(Beijing, Tianjin)            | 618  | 0.0348           |
| BW.Zhang [27]   | Asian         | North China(Henan province)              | 3874 | 0.0484           |
| P.Qin Qin [28]  | Asian         | Between the north and south              | 3258 | 0.0485           |
| WX.Li [29]      | Asian         | South China(Hubei province)              | 1013 | 0.0479           |
| Z.Li [30]       | Asian         | South China(Guangdong)                   | 20621| 0.0531           |
| Chen PL [31]    | Asian         | China Taiwan                             | 504  | 0.0870           |
| ShuHui Wen [32] | Asian         | China Taiwan                             | 710  | 0.0880           |
| CF Pan [33]     | Asian         | China Taiwan                             | 855  | 0.0740           |
| Meng Jun        | Asian         | China Taiwan                             | 46682| 0.1103           |
| T.Tanaka [35]   | Asian         | Japan                                    | 525  | 0.0040           |
| Hashimoto       | Asian         | Japan                                    | 916  | 0.0020           |
| Inoko H [37]    | Asian         | Japan                                    | 1018 | 0.0010           |
| Shigeki         | Asian         | Japan                                    | 1616 | 0.0003           |
| M.H.Park [39]   | Asian         | Korea                                    | 510  | 0.0196           |
| M.H.Park [40]   | Asian         | Korea                                    | 800  | 0.0230           |
| Eun Young       | Asian         | Korea                                    | 800  | 0.0225           |
| Maiers M [42]   | Asian         | USA                                      | 1772 | 0.0537           |
| Maiers M [42]   | Asian         | USA                                      | 2411 | 0.0707           |
| Clinimmune      | Hispanic      | USA                                      | 1058 | 0.0630           |
| Maiers M [42]   | Hispanic      | USA                                      | 1999 | 0.0733           |
| W.Klitz [43]    | Hispanic      | USA                                      | 553  | 0.0678           |
| Wang SS [44]    | European ancestry | USA                                    | 1070 | 0.1039           |
| NAVAL MEDICAL   | European ancestry | USA                                    | 61655| 0.1250           |
| Clinimmune      | European ancestry | USA                                    | 3830 | 0.1210           |
| Steven          | Southern European | USA                                    | 552  | 0.0987           |
| Steven          | Eastern European | USA                                    | 558  | 0.1022           |
| Schmidt AH [47] | Eastern European | Poland                                | 20653| 0.1053           |
| Schmidt AH [48] | Western European | German                                | 8862 | 0.1087           |
| Middleton D [49]| Western European | Ireland Northern                      | 1000 | 0.1600           |
| Silvia Vidal    | Western European | Spain Barcelona                      | 941  | 0.1200           |
| S Meyer         | Western European | Swiss                                | 3093 | 0.0972           |

These data information were collected from the Allele Frequency Net Database [52] except reference 25,27–30,33–34,38–39,41,45,51. Allele Frequency: Total number of copies of the allele in the population sample (Alleles/2n) in decimal format. a: data from Chinese National Marrow Donor Program(CNMDP), b: data from Tzu Chi Taiwan Marrow Donor Registry (TCTMDR), c: data from USA Colorado Univ. Cord Blood Bank, d: data from Poland DKMS, e: data from Umbilical Cord Blood Bank of Barcelona, f: data in Allele frequency net was calculated from Phenotype Frequencies assuming Hardy-Weinberg proportions.

doi:10.1371/journal.pone.0048594.t003

Discussion

In this study, we found that HLA-DRB1 alleles may be contributing to susceptibility to sporadic PD in the Chinese Han population in the Guangdong Province of PRC. The allele frequency of HLA-DRB1*03 was significantly higher in PD patients than in healthy controls (0.0811 vs. 0.0449, pc = 4.572E-3, statistic power > 0.75), which was identical with the report in European ancestry populations [16]. Furthermore, we found that HLA-DRB1*0301, the most common subtype of HLA-DRB1*03, had a strong association with PD development.

HLA-DRB1*0301 has been reported to contribute to the genetic susceptibility of some autoimmune diseases such as type 1 diabetes and multiple sclerosis [53–54]. In our study, the allele frequency of HLA-DRB1*0301 was significantly higher in PD patients than in healthy controls (0.0811 vs. 0.0449, pc = 4.572E-3, statistic power > 0.75). Furthermore, the allele frequency was significantly higher in patients with an onset age ≤50 than in patients with an onset age >50 (0.0678 vs. 0.0342, pc = 0.012, statistic Power >0.75), suggesting that people carrying the HLA-DRB1*0301 allele may have a tendency for an early onset of PD. Molecules encoded by polymorphic HLA alleles elicit different T-cell killing effects by presenting different peptide-binding preferences [55]. In pulmonary sarcoidosis, patients carrying the HLA-DRB1*0301 allele have shown more CD8 T-cells than those carrying other HLA-DRB1 alleles [56–57].
Table 4. The tag SNPs of HLA-DRB1 alleles in four HapMap populations.

| HLA-DRB1 alleles | CHB | JPT | CEU | YRI |
|------------------|-----|-----|-----|-----|
| 0301             | rs5000803 | –  | rs2040410 | rs2040410 |
|                  | rs3129299 | –  | rs2187688 | rs9277489 |
|                  | rs7769979 | –  | –  | rs2040410 |
| 0401             | –  | rs1150758 | –  | rs3129763 |
| 0403             | rs2075800 | rs169494 | rs7454108 | –  |
|                  | rs2395175 | rs3763349 | rs206765 | –  |
|                  | –  | –  | rs399604 | –  |
| 0406             | –  | rs2395175 | –  | –  |
| 0701             | rs3129859 | rs6936863 | rs7745002 | –  |
| 0802             | –  | rs3129888 | –  | –  |
| 0803             | rs3129859 | rs2395148 | –  | –  |
| 0901             | rs2395185 | rs2187818 | –  | –  |
| 1201             | –  | –  | rs4248166 | –  |
| 1202             | rs6916742 | rs4418214 | –  | –  |
|                  | rs646984 | –  | –  | –  |
| 1301             | rs4947342 | –  | rs2395173 | rs3134942 |
| 1302             | rs11758998 | rs6936204 | rs4434496 | rs2157339 |
| 1401             | –  | –  | rs1612904 | –  |
| 1406             | –  | rs3129888 | –  | –  |
| 1501             | rs7773756 | –  | –  | –  |
| 1502             | rs2858880 | rs3133565 | rs2858880 | –  |

Tag SNPs were obtained from the references [75–80]. The tag SNP has not been detected. rs2975229 has merged into rs2858324. CHB: Han Chinese in Beijing, JPT: Japanese in Tokyo, CEU: Utah Residents with Northern and Western European Ancestry, YRI: Yoruba in Ibadan, Nigeria.

doi:10.1371/journal.pone.0048594.t004

Interestingly, several studies reported that regulatory T-cells could mediate neuroprotection through modulation of microglia oxidative stress and inflammation, while profound T-cell responses could exacerbate neuroinflammation and induce dopaminergic neurodegeneration [58–61]. Thus, we speculated that the HLA-DRB1*0301 allele may be related to younger patients through eliciting strong inflammatory responses.

The HLA-DRB1*0406 allele, a subtype of HLA-DRB1*04, probably play a role to prevent the development of sporadic PD deserves debate. The HLA-DRB1*0406 allele is rare in European ancestry populations, but common in Asian ancestry populations [25–52]. Previous studies have shown that it is associated with susceptibility to insulin autoimmune syndrome, silicosis, prostate cancer, and pemphigus in Asian ancestry populations [62–65], which implied that HLA-DRB1*0406 is a risk allele for immune dysfunction diseases. In our study, the allele frequency of HLA-DRB1*0406 in PD patients was significantly lower than in healthy controls (0.0013 vs. 0.0308, p = 3.295E-5, statistic Power = 1), this inconsistency may be due to a sampling bias. We noticed that the allele frequencies of HLA-DRB1*0403, another subtype of HLA-DRB1*04, was presented higher in PD patients than in healthy controls in series 1 although the difference was not significant after Bonferroni adjustment (0.0307 vs. 0.0159, p = 0.035, PC = 1). There was no report that HLA-DRB1*04 have two opposing effects in the disease. Therefore, whether HLA-DRB1*0406 plays a unique neuroprotective role in the PD development of Chinese Han population still needs to be investigated.

After summarizing the allele frequencies of HLA-DRB1*0401 and HLA-DRB1*0406 in populations from various ethnic regions, we confirmed that the distribution of the two HLA-DRB1 alleles was highly polymorphic with different ethnic and geographic, this phenomenon was more obviously in vast and complicated races regions, such as mainland China, China Taiwan, and America. We also found a higher frequency of HLA-DRB1*0301, but a lower frequency of HLA-DRB1*0406 in European ancestry populations than in Asian ancestry populations. This was consistent with the higher prevalence of PD in European ancestry populations than in Asian ancestry populations [66–69]. However, we could not analyze the correlation between the allele frequencies of these loci and prevalence of sporadic PD because the allele frequency data was incomplete and the prevalence data was collected using different methodologies in the worldwide populations.

We noticed that the allele frequencies of HLA-DRB1*1202, DRB1*1312, and DRB1*1454 were also higher in PD patients than in healthy controls. However, the difference was not significant after Bonferroni adjustment, the statistic power in these alleles are at moderate level (0.5 < statistic Power < 0.75). Several studies reported these alleles unequivocally associated with immune-related diseases [70–74]. The possibility cannot be ruled out that these alleles may be either susceptibility genes or linkage disequilibrium with other susceptibility genes contributing to the etiology of PD. In addition, some rare alleles were detected because of random sampling, we lost most of the statistical power in these alleles due to their very small allele frequencies.

Recent studies have shown that some common HLA alleles can be marked with SNP-based tags [75–80]. We listed tag SNPs of the HLA-DRB1 alleles (Table 4), and compared it with the reported genetic susceptibility SNPs in the HLA-DR region to sporadic PD in European ancestry populations. We found that (i) these tag SNPs are all located at a considerable distance from the HLA-DRB1 allele, (ii) tag SNPs are likely to differ between populations, HLA-DRB1*0406 in JPT, HLA-DRB1*0403 in CHB (Han Chinese in Beijing) shared the same tag SNPs rs2395175, our study showed that HLA-DRB1*0403 was more common in PD patients than in controls, but the difference was no statistic significance, that partially explained why PD GWAS study in Japanese saw no evidence of HLA association even though the HLA-DRB1*0406 allele appears more frequent in Japan [20], (iii) rs3129859 (tag HLA-DRB1*0701 in CHB), rs3129888 (tag HLA-DRB1*0802, DRB1*1406 in JPT), and rs3763313 (tag HLA-DRB1*0803 in JPT) have been reported in association with the genetic susceptibility to PD in European ancestry populations [17–19], but there was no evidence showed that HLA-DRB1*0701, -DRB1*0802,-DRB1*1406 were also higher in PD patients than in healthy controls. However, the difference was not significant after Bonferroni adjustment (0.0307 vs. 0.0159, p = 0.035, PC = 1). There was no report that HLA-DRB1*04 have two opposing effects in the disease. Therefore, whether HLA-DRB1*0406 plays a unique neuroprotective role in the PD development of Chinese Han population still needs to be investigated.

In conclusion, our study indicated that HLA-DRB1 alleles are associated with sporadic PD in Chinese Han population, further research will be required to explore the role of HLA-DRB1 alleles in the pathogenesis of Parkinson’ disease.

Acknowledgments

We sincerely thank professor Jinxin Zhang from department of Biostatistics and Epidemiology in Sun Yat-Sen University for the guidance in statistical analysis.
Author Contributions
Conceived and designed the experiments: CZ PX. Performed the experiments: CS LW FL YL LX. Analyzed the data: CS. Contributed reagents/materials/analysis tools: JL FZ PK RX. Wrote the paper: CS PX.

References
1. Lang AE, Lozano AM (1998) Parkinson’s disease. Second of two parts. N Engl J Med 339: 1130–1143.
2. Monahan AJ, Warren M, Carvey PM (2008) Neuroinflammation and peripheral immune infiltration in Parkinson’s disease: an autoimmune hypothesis. Cell Transplant 17: 363–372.
3. Rose-Berman F, Hunot S, Herrero MT, Parmadeau S, Corvol JC, et al. (2011) Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A 108: 6632–6637.
4. Yong J, Lacan G, Dang H, Hach S, Middleton B, et al. (2011) BCG vaccine-induced neuroprotection in a mouse model of Parkinson’s disease. PLoS One 6: e16610.
5. Mecerrey PL, Izaaki S, Boyes RE, Mecerrey EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38: 1285–1291.
6. Klein J, Sato A (2006) The HLA system. First of two parts. N Engl J Med 349: 792–796.
7. Handunnetthi L, Ramagopalan SV, Ebers GC, Knight JC (2010) Regulation of major histocompatibility complex II gene expression, genetic variation and disease. Genes Immun 11: 99–112.
8. Zota V, Nemirovsky A, Baron R, Fisher Y, Seeko DJ, et al. (2009) HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J Immunol 183: 3522–3530.
9. Ma SL, Tang NL, Tam CW, Lui VW, Suen EW, et al. (2008) Association between HLA alleles and Alzheimer’s disease in a southern Chinese community. Dement Geriatr Cogn Disord 26: 391–397.
10. Guerini FR, Tinelli C, Calabrese E, Agliardi C, Zanotter M, et al. (2009) HLA-A*0101 is associated with late onset of Alzheimer’s disease in Italian patients. Int J Immunopharmacol 32: 991–999.
11. Nell D, Curran MD, Middleton D, Mavshynie H, Edwardson JA, et al. (1999) Risk for Alzheimer’s disease in older late-onset cases is associated with HLA-DRB1*03. Neurosci Lett 273: 137–140.
12. Naujokas RM, Kimme UK, Tilkanik A (1998) Histocompatibility types in marrow donors based on donor–recipient confirmatory typings. HLA-A, -B, -Cw, -DRB1, and -DQB1 alleles and haplotypes in 718 Chinese loci. Cell Res 15: 97–98.
13. Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, et al. (2010) Comprehensive genotyping in two homogeneous Graves’ disease samples reveals major and novel HLA association alleles. PLoS One 6: e16635.
14. Wen SH, Lai MJ, Yang KL (2008) Human leukocyte antigen-A, -B, and -DRB1 haplotypes of cord blood units in the Tsu Chi Taiwan Cord Blood Bank. Hum Immunol 69: 430–436.
15. Pan CF, Wu CJ, Chen HH, Dang CW, Chang FM, et al. (2009) Molecular analysis of HLA-DRB1 allele associations with systemic lupus erythematosus and lupus nephritis in Taiwan. Lupus 18: 698–704.
16. Lai MJ, Wen SH, Lin YH, Shyr MH, Lin PY, et al. (2010) Distributions of human leukocyte antigen-A, -B, and -DRB1 alleles and haplotypes based on 46,915 Taiwanese donors. Hum Immunol 71: 777–782.
17. Tanaka T, Ohnouru M, Yasumaga S, Ohshima K, Kikuchi M, et al. (1999) DNA typing of HLA class II genes (HLA-DR, -DQ and -DP) in Japanese patients with histiocytic necrotizing lymphadenitis (Kikuchi’s disease). Tissue Antigens 53: 246–253.
18. Hashimoto K, Kinoshita T, Yamashiki M, Tanaka H, Inamishi T, et al. (1994) Gene frequencies and haplotype associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 44: 166–173.
19. Roh Y, Mizuki N, Shimada T, Arzama F, Inakura M, et al. (2005) High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 57: 717–729.
20. Mitsunaga S, Homma Y, Narita A, Kashivase K, Okudaira Y, et al. (2011) Particular human leukocyte antigen alleles are associated with biochemical traits in the Japanese population. Tissue Antigens 78: 781–785.
21. Park MH, Kim HS, Kang SJ (1999) HLA-A,-B, and DRB1 allele and haplotype frequencies in 510 Koreans. Tissue Antigens 53: 386–390.
22. Song EY, Park H, Roh EY, Park MH (2004) HLA-DRB1 and -DQB1 allele frequencies and haplotype associations in Koreans. Hum Immunol 65: 270–276.
23. Song EY, Park S, Lee DS, Cho HI, Park MH (2008) Association of human leukocyte antigen-DRB1 alleles with disease susceptibility and severity of aplastic anemia in Korean patients. Hum Immunol 69: 354–359.
24. Maiers M, Gragert L, Kiitz W (2007) High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 68: 779–781.
25. Kiitz W, Gragert L, Maiers M, Tu B, Lazarou A, et al. (2009) Four-focus high-resolution HLA typing in a sample of Mexican Americans. Tissue Antigens 74: 500–513.
26. Wang SS, Ahlou AM, Morton LM, Thomas R, Gerhan JR, et al. (2010) Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood 115: 4020–4023.
27. Mack SJ, Tu B, Yang R, Masaberg C, Ng J, et al. (2011) Human leukocyte antigen-A,-B,-C,-DRB1 allele and haplotype frequencies in Americans originating from southern Europe: contrasting patterns of population differentiation between Italian and Spanish Americans. Hum Immunol 72: 144–149.
28. Mack SJ, Tu B, Lazarou A, Yang R, Lancaster AK, et al. (2009) HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population. Tissue Antigens 73: 17–32.
29. Schmidt AH, Solloch UV, Pangel J, Baier D, Bohme I, et al. (2011) High-resolution human leukocyte antigen allele and haplotype frequencies of the Polish population based on 20,653 stem cell donors. Hum Immunol 72: 558–563.
30. Schmidt AH, Baier D, Solloch UV, Stahr A, Cereb N, et al. (2009) Estimation of high-resolution HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies based on 8992 German stem cell donors and implications for strategic donor registry planning. Hum Immunol 70: 995–1002.
31. Middleton D, Williams F, Hamill MA, Meneough A (2000) Frequency of HLA-A alleles in amyloidosis originating from southern Europe: contrasting patterns of population differentiation between Italian and Spanish Americans. Hum Immunol 72: 144–149.
50. Vidal S, Morante MP, Moga E, Mosquera AM, Querol S, et al. (2002) Molecular analysis of HLA-DRB1 polymorphism in north-east Spain. Eur J Immunogenet 29: 75–77.

51. Meyer-Monard S, Pasweg J, Troeger C, Eberhard HP, Roennek E, et al. (2009) Cord blood banks collect units with different HLA alleles and haplotypes to volunteer donor banks: a comparative report from Swiss Blood stem cells. Bone Marrow Transplant 43: 771–778.

52. Gonzalez-Galarza FF, Christman S, Middledon D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39: D913–919.

53. Manan H, Agham AM, Setiabhatani A (2010) Genetic and diabetic autoantibody markers in Saudi children with type 1 diabetes. Hum Immunol 71: 1238–1242.

54. de la Concha EG, Cavanillas ML, Cnin MT, Urcelay E, Arroyo R, et al. (2012) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3: e1376.

55. Kaufman JF, Auffray C, Shackelford DA, Strominger J (1984) The identification of monoclonal insulin autoantibodies in insulin autoimmune syndrome associated with HLA-DRB1*0401. Horm Res 54: 49–52.

56. Idali F, Wiking M, Wahlström J, Mellstedt H, Eklund A, et al. (2006) Reduced cell infiltration of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol 82: 1083–1094.

57. Wiking M, Eklund A, Wahlström J, Mellstedt H, Eklund A, et al. (2012) HLA-DRB1 Alleles Associated with Parkinson Disease in Chinese Patients with Pemphigus. Tissue Antigens 54: 333–340.

58. Zhang Z, Roman GC, Hong Z, Wu CB, Qu QM, et al. (2003) Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365: 595–597.

59. von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, et al. (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15: 473–480.

60. Driver JA, Logroscino G, Gazziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72: 432–438.

61. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, et al. (2007) Neuroprotective activities of CD4+CD25+ regulatory T cells in a mouse model of Parkinson’s disease. J Clin Invest 119: 182–192.

62. Monos DS, Papaioakim M, Ho TW, Li CY, Mckhann GM (1997) Differential specific association with the presence of intrathecal IgM bands. PLoS One 7: e31018.

63. Ueki A, Isozaki Y, Kusaka M (2005) Anti-caspase-8 autoantibody response in Japanese patients with pemphigus. Tissue Antigens 54: 333–340.

64. Miyagawa S, Amagai M, Niizeki H, Yamashina Y, Kaneshige T, et al. (1999) HLA-DRB1 polymorphisms and autoimmune responses to desmogleins in Japanese patients with pemphigus. Tissue Antigens 54: 333–340.

65. Zhang Z, Roman GC, Hong Z, Wu CB, Qu QM, et al. (2003) Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365: 595–597.

66. Driver JA, Logroscino G, Gazziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72: 432–438.

67. Würdefeld K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 26 Suppl 1: S1–S10.

68. Chun-Lai T, Padyukov L, Dhalivval S, Lundstrom E, Yalhya A, et al. (2011) Shared epitope alleles remain a risk factor for anti-citrullinated proteins antibody (ACPA)–positive rheumatoid arthritis in three Asian ethnic groups. PLoS One 6: e10206.

69. Wirdefeld K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese patients. Hum Immunol 72: 422–425.

70. Saha M, Harman K, Mortimer NJ, Binda V, Black MM, et al. (2010) Prevalence of Pemphigus Vulgaris in White Europeans is linked with HLA Class II Allele HLA-DRB1*1401 but not HLA-DRB1*0101. J Invest Dermatol 130: 311–314.

71. Miretti MM, Wahls EC, Ke X, Delgado M, Griffiths M, et al. (2005) A high-resolution linkage disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 76: 634–646.

72. de Bakker PI, McVean G, Sabaté PC, Miretti MM, Green T, et al. (2006) A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 38: 1166–1172.

73. Leslie S, Douenel P, McVean G (2000) A statistical method for predicting classical HLA alleles from SNP data. Am J Hum Genet 82: 48–56.

74. Takahara S, Nonomura N, Sada M, Tsuji T, et al. (2000) HLA-DRB1 genotypes in Japanese patients with renal cell carcinoma. Oncology 59: 57–62.

75. Miretti MM, Walsh EC, Ke X, Delgado M, Griffiths M, et al. (2005) A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 76: 634–646.

76. de Bakker PI, McVean G, Sabaté PC, Miretti MM, Green T, et al. (2006) A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 38: 1166–1172.

77. Leslie S, Douenel P, McVean G (2000) A statistical method for predicting classical HLA alleles from SNP data. Am J Hum Genet 82: 48–56.

78. Takahara S, Nonomura N, Sada M, Tsuji T, et al. (2000) HLA-DRB1 genotypes in Japanese patients with renal cell carcinoma. Oncology 59: 57–62.

79. McElroy JP, Isobe N, Gourraud PA, Caillier SJ, Matsushita T, et al. (2011) SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients. Genes Immun 12: 523–530.

80. Kitajima H, Sonoda M, Yamamoto K (2012) HLA and SNP haplotype mapping in the Japanese population. Genes Immun 13: 1–13.